Salvina Therapeutics AG, a recently founded Swiss company, is developing new therapies to break efficacy ceilings in inflammatory and autoimmune diseases.
The company has unlocked a novel epitope for selectively targeting TNF, resulting in the generation of antibodies with a highly innovative mode of action.
Salvina
